Platform Achievements:
OriCell Therapeutics for the First Time Discloses Its Clinical Research Progress of Ori®TIL-001 for Treatment of Osteosarcoma Pulmonary Metastases at the 2021 CSCO Annual Meeting, Showing Promising Safety Results.
The 24th Annual Meeting of Chinese Society of Clinical Oncology (2021 CSCO Annual Meeting) was held online on September 25–29, 2021. OriCell Therapeutics presented its clinical research progress of Ori®TIL-001 for treatment of osteosarcoma pulmonary metastases (Registration No. ChiCTR1900026789) for the first time at the "Special Session on Bone and Soft Tissue Sarcoma". Professor Hua Yingqi from the Department of Bone Oncology, Shanghai General Hospital (cooperation partner) delivered a speech titled "Exploratory study on the safety and efficacy of autologous tumor infiltrating lymphocytes in the treatment of patients with pulmonary metastases from osteosarcoma".
